HiFiBiO Therapeutics

OverviewSuggest Edit

HiFiBiO Therapeutics is a biotherapeutics company. The company integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies. It allows discovering and advancing a pipeline of antibody drugs to treat cancer and autoimmune disorders.

TypePrivate
Founded2013
HQParis, FR
Websitehifibio.com

Latest Updates

Employees (est.) (Jan 2021)69(+2%)
Cybersecurity ratingAMore

Key People/Management at HiFiBiO Therapeutics

Liang Schweizer

Liang Schweizer

Chief Executive Officer & Chief Scientific Officer
Jeff He

Jeff He

Chief Operating Officer
Xuqiong Wu

Xuqiong Wu

General Counsel
Show more

HiFiBiO Therapeutics Office Locations

HiFiBiO Therapeutics has offices in Paris, Cambridge and Shanghai
Paris, FR (HQ)
29 Rue du Faubourg Saint-Jacques
Shanghai, CN
1077 Zhangheng Rd, Pudong Xinqu
Cambridge, MA, US
237 Putnam Ave
Show all (3)

HiFiBiO Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2013

HiFiBiO Therapeutics total Funding

$104.5 m

HiFiBiO Therapeutics latest funding size

$67 m

Time since last funding

a year ago

HiFiBiO Therapeutics investors

HiFiBiO Therapeutics's latest funding round in August 2019 was reported to be $67 m. In total, HiFiBiO Therapeutics has raised $104.5 m
Show all financial metrics

HiFiBiO Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

HiFiBiO Therapeutics Online and Social Media Presence

Embed Graph

HiFiBiO Therapeutics Blogs

HiFiBiO Therapeutics Inks Partnership with Pharmsynthez and IBCh for the Clinical Development and Commercialization of its SARS-CoV-2 Neutralizing Antibody in Russia

IND for HFB30132A submitted to the Ministry of Health of the Russian Federation and clinical sites selected for a Phase I/II, randomized, double-blind, placebo-controlled, two-stage, multicenter study CAMBRIDGE, Mass. – November 23, 2020 – HiFiBiO Therapeutics, a multinational biotherapeutics compan…

HiFiBiO Therapeutics CEO Liang Schweizer Named one of the World’s Top Female Founders

Dr. Schweizer continues to be recognized for long-term vision, open-innovation strategy, commitment to diversity, and ability to secure more than $100 million in financing CAMBRIDGE, Mass. – October 27, 2020 – HiFiBiO Therapeutics, a multinational biotherapeutics company with unique expertise in imm…

HiFiBiO Therapeutics Completes First Cohort of a Phase I Study of its SARS-CoV-2 Neutralizing Antibody for the Treatment and Prevention of COVID-19

HFB30132A study design is published in ClinicalTrial.gov and primary data readout is expected in late 2020 CAMBRIDGE, Mass. – October 26, 2020 – HiFiBiO Therapeutics, a multinational biotherapeutics company with unique expertise in immune modulation and single-cell science, today announced the succe…

HiFiBiO Therapeutics CEO Liang Schweizer Receives 2020 Extraordinary Women Advancing Healthcare Award

The Commonwealth Institute Recognizes Women Leaders in Massachusetts Demonstrating Impact, Inspiration, and Innovation across Healthcare Industry CAMBRIDGE, Mass., – September 24, 2020 – HiFiBiO Therapeutics today announced its CEO, Liang Schweizer, PhD, has been recognized with an Extraordinary Wom…

HiFiBiO Therapeutics Presents Novel Approach to Patient Stratification Demonstrating DIS™ Single-Cell Platform at 2020 AACR Tumor Heterogeneity Conference

CAMBRIDGE, Mass., – September 17, 2020 – HiFiBiO Therapeutics is presenting a novel approach for patient stratification demonstrating its proprietary Drug Intelligent Science (DIS™) single-cell platform at the American Association for Cancer Research (AACR) Tumor Heterogeneity Virtual Special Confer…

HiFiBiO Therapeutics Announces a Global Strategic Partnership with ABL Bio for the Co-Development of a SARS-CoV-2 Neutralizing Antibody

CAMBRIDGE, Mass., PARIS, SHANGHAI, and HONG KONG– September 14, 2020 – HiFiBiO Therapeutics, a clinical-stage multinational biotherapeutics company focused on the development of novel antibodies in immunomodulation, today announced a partnership agreement with South Korea-based ABL Bio to advance HF…
Show more

HiFiBiO Therapeutics Frequently Asked Questions

  • When was HiFiBiO Therapeutics founded?

    HiFiBiO Therapeutics was founded in 2013.

  • Who are HiFiBiO Therapeutics key executives?

    HiFiBiO Therapeutics's key executives are Liang Schweizer, Jeff He and Xuqiong Wu.

  • How many employees does HiFiBiO Therapeutics have?

    HiFiBiO Therapeutics has 69 employees.

  • Who are HiFiBiO Therapeutics competitors?

    Competitors of HiFiBiO Therapeutics include Sphere Fluidics, Spiral Therapeutics and CMG Pharmaceutical.

  • Where is HiFiBiO Therapeutics headquarters?

    HiFiBiO Therapeutics headquarters is located at 29 Rue du Faubourg Saint-Jacques, Paris.

  • Where are HiFiBiO Therapeutics offices?

    HiFiBiO Therapeutics has offices in Paris, Cambridge and Shanghai.

  • How many offices does HiFiBiO Therapeutics have?

    HiFiBiO Therapeutics has 3 offices.